France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

pierre fabre dermatologie - jusquiame (huile de) composee - pommade - 6,000 g - composition pour 100 g de pommade > jusquiame (huile de) composee : 6,000 g > cade (huile de) : 6,000 g > acide salicylique : 0,900 g - antipsoriasique topique

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

institut pharmaceutique de recherche d'application et developpement - jusquiame noire (feuille de) (extrait fluide de) - crème - 2,000 g - composition pour 100 g de crème > jusquiame noire (feuille de) (extrait fluide de) : 2,000 g > genet a balai (extrait fluide de) : 2,000 g > arnica (extrait fluide d') : 0,800 g > marron d'inde (extrait de) (sec) : 0,400 g

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

amex - jusquiame noire (teinture de) - solution - 17,22 g - composition pour 100 ml > jusquiame noire (teinture de) : 17,22 g > belladone (teinture de) : 39,61 g

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

zambon france - acétylcystéine 1; benzalkonium (chlorure de) 0; tuaminoheptane (sulfate de) 0 - solution - 1,0000 g - pour 100 ml > acétylcystéine 1,0000 g > benzalkonium (chlorure de 0,0125 g sous forme de : benzalkonium (chlorure de), solution de > tuaminoheptane (sulfate de 0,5000 g - sympathomimétiques en association - classe pharmacothérapeutique - code atc : sympathomimétiques en association, sauf aux corticoïdes - r01ab08.ce médicament contient un sympathomimétique alpha, vasoconstricteur décongestionnant par voie nasale, le sulfate de tuaminoheptane, un antiseptique, le chlorure de benzalkonium, et un mucolytique, l’acétylcystéine.ce médicament est indiqué pour le traitement symptomatique local, de courte durée, des affections rhinopharyngées (rhume, rhinite), avec sécrétion excessive de la muqueuse de l’adulte et des adolescents de plus de 15 ans.

Union européenne - français - EMA (European Medicines Agency)

amryt pharmaceuticals dac - dry extract from birch bark (der 5-10 : 1), extraction solvent n-heptane 95% (w/w) - epidermolysis bullosa dystrophica; epidermolysis bullosa, junctional - préparations pour le traitement des plaies et des ulcères - treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (eb) in patients 6 months and older.

Union européenne - français - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

jntl consumer health ii (switzerland) gmbh - nicotinum - dispositif transdermique - nicotinum 15.75 mg, triglycerida media, copolymerum methacrylatis butylati basicum, 2-ethylhexylacrylate/butyracryltate/vinylacetate/acrylic acid copolymer (75:15:5:5) in ethylacetate/heptane (85:15), kalii hydroxidum, carmellosum natricum conexum, aluminii acetylacetonas pro praeparatione cum liberatione 10 mg/16h. - le soutien de l'arrêt du tabac - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

jntl consumer health ii (switzerland) gmbh - nicotinum - dispositif transdermique - nicotinum 23.62 mg, triglycerida media, copolymerum methacrylatis butylati basicum, 2-ethylhexylacrylate/butyracryltate/vinylacetate/acrylic acid copolymer (75:15:5:5) in ethylacetate/heptane (85:15), kalii hydroxidum, carmellosum natricum conexum, aluminii acetylacetonas pro praeparatione, cum liberatione 15 mg/16h. - le soutien de l'arrêt du tabac - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

jntl consumer health ii (switzerland) gmbh - nicotinum - dispositif transdermique - nicotinum 39.37 mg, triglycerida media, copolymerum methacrylatis butylati basicum, 2-ethylhexylacrylate/butyracryltate/vinylacetate/acrylic acid copolymer (75:15:5:5) in ethylacetate/heptane (85:15), kalii hydroxidum, carmellosum natricum conexum, aluminii acetylacetonas pro praeparatione, cum liberatione 25 mg/16h. - le soutien de l'arrêt du tabac - synthetika

Canada - français - Health Canada

patriot a division of janssen inc - rabéprazole sodique - comprimé (entérosoluble) - 10mg - rabéprazole sodique 10mg - proton-pump inhibitors